Veeva Systems has announced that Novo Nordisk’s International Operations business unit has officially committed to adopting Veeva Vault CRM, marking an important step in strengthening the company’s global commercial technology strategy. This decision reflects Novo Nordisk’s focus on modernizing its customer engagement platforms while ensuring compliance with complex, country-specific pharmaceutical regulations.
As life sciences organizations continue to expand across markets, they face growing pressure to manage increasingly complex commercial operations. Therefore, having a unified and intelligent CRM system has become essential for improving coordination between field teams, digital engagement platforms, and compliance processes. By choosing Vault CRM, Novo Nordisk aims to streamline how its commercial teams operate across personal and digital channels while maintaining strict regulatory standards.
Veeva CEO Peter Gassner welcomed the expanded collaboration and highlighted the shared mission behind the partnership. He said:
"We are honored to expand our partnership with Novo Nordisk to Vault CRM," said Veeva CEO Peter Gassner. "Working together with AI-driven technology, we will do our part to help Novo Nordisk deliver breakthrough medicines to defeat serious chronic diseases and create long-term health for patients around the world."
Vault CRM is part of the broader Vault CRM Suite, which brings together deep commercial applications and agentic AI to help organizations execute more effective go-to-market strategies. In addition to supporting traditional sales models, the platform also enables coordinated engagement across digital channels, ensuring consistent communication with healthcare professionals and stakeholders. Moreover, the suite is designed to address evolving compliance needs that vary from country to country, making it suitable for large multinational pharmaceutical organizations.
Furthermore, Vault CRM’s advanced global capabilities allow companies to manage local market requirements while maintaining centralized visibility and governance. This balance is especially critical for global enterprises like Novo Nordisk, where teams must adapt to local regulations without losing operational consistency.
From Novo Nordisk’s perspective, the move to Vault CRM supports its long-term digital transformation roadmap. Emil Kongshøj Larsen, executive vice president, International Operations at Novo Nordisk, emphasized the strategic value of the platform, stating:
"We are excited to expand our strategic partnership with Veeva by moving to Vault CRM," said Emil Kongshøj Larsen, executive vice president, International Operations at Novo Nordisk. "Vault CRM will help provide Novo Nordisk the technology foundation to help drive commercial execution."
By adopting Vault CRM, Novo Nordisk expects to enhance collaboration across teams, improve data-driven decision-making, and strengthen engagement with healthcare providers. At the same time, the platform’s AI-driven features can support smarter targeting, content recommendations, and performance insights, helping commercial teams focus on the most impactful activities.
Additionally, this commitment highlights a broader industry trend toward cloud-based, AI-enabled commercial platforms that support omnichannel engagement. As pharmaceutical companies seek to improve efficiency while maintaining compliance, platforms like Vault CRM are becoming central to their commercial operations.
Overall, the expanded partnership between Veeva Systems and Novo Nordisk underscores a shared commitment to innovation, scalability, and patient-centered outcomes. By aligning advanced CRM technology with global commercial needs, both companies aim to support more effective medicine delivery and long-term health improvements worldwide.
To join our expert panel discussions, reach out to info@intentamplify.com
Recommended News